HK Stock Market Move | KINTOR PHARMA-B (09939) rose nearly 9% again as its subsidiary signed a strategic cooperation framework agreement with Shanghai Kangmei for KT-939.

KINTOR PHARMA-B (09939) rose nearly 9% again, and as of the time of writing, it was up 6.35% at HKD 2.01, with a trading volume of HKD 1.8253 million. In news, on August 5, Suzhou Kintor, a subsidiary of Kintor Pharma, established a strategic partnership with Shanghai Kangmei, a subsidiary of Libon Kangmei. They will collaborate on the application transformation of the functional ingredient KT-939 in the cosmetics field, including formula development, process validation, and ODM/OEM production. They aim to jointly promote the standardized application and industrial transformation of related innovative results in the cosmetics field. Suzhou Kintor will leverage its advantages in functional ingredients and related R&D technologies, while Shanghai Kangmei will utilize its capabilities in cosmetics formula development, sample trial production, process scaling, quality management, and large-scale manufacturing. The framework agreement established with Shanghai Kangmei aims to build a long-term and stable strategic partnership, fully utilizing both sides' complementary advantages in the research and development of innovative ingredients and the development and manufacturing of skincare products, to promote the market transformation and business expansion of the functional cosmetic ingredient KT-939.